Use of belumosudil for the treatment of chronic graft-versus-host disease
Open Access
- 17 July 2026
- journal article
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 202-209
Abstract
Chronic graft-versus-host disease (cGVHD) is one of the most significant late complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT). First-line therapy is based on glucocorticosteroids; however, a substantial proportion of patients develop steroid-refractory disease requiring subsequent lines of treatment. In recent years, targeted therapies have been introduced into clinical practice, including belumosudil, a selective ROCK2 inhibitor. Aim : to evaluate the efficacy and safety of belumosudil in patients with severe steroid-refractory cGVHD. Main findings. In the presented case series, patients with severe cGVHD with lung involvement, refractory to glucocorticosteroids and prior therapies (including JAK inhibitors, antifibrotic, and immunomodulatory agents), received belumosudil as thirdor later-line treatment. Partial response was achieved in one patient, while disease stabilization was observed in two patients. In all cases, the treatment demonstrated a favorable safety profile, with no serious adverse events requiring discontinuation. These findings suggest that belumosudil is clinically effective in heavily pretreated patients, including those with advanced pulmonary involvement. However, the limited reversibility of fibrotic changes supports the rationale for earlier initiation of therapy.Keywords
This publication has 21 references indexed in Scilit:
- FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic TherapyClinical Cancer Research, 2022
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD ReportTransplantation and Cellular Therapy, 2021
- Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2018
- Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic TargetsNew England Journal of Medicine, 2017
- Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2016
- Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group ReportTransplantation and Cellular Therapy, 2015
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015
- Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanismProceedings of the National Academy of Sciences, 2014
- Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concernsBlood, 2010
- Chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2003